Proper collection of infectious biosamples is critically important for better understanding of the disease pathogenesis and health. These precious samples are stored in biobanks. COVID-19 is an infectious disease caused by the recently discovered novel coronavirus named SARS-COV-2. Currently, specific drugs are not available against this virus though efforts on development of vaccines by various agencies have shown some positive results. Limited knowledge about the pathogenesis mechanism is a critical gap in developing intervention options. Access of COVID-19 biosamples for research could provide more insight into the disease. The Indian Council of Medical Research (ICMR) designated National Liver Disease Biobank (NLDB) as one of the dedicated facilities for collection and storage of COVID-19 biosamples for research purposes. Samples are collected, processed, and stored with proper security at NLDB. In this minireview, we have made an attempt to provide comprehensive coverage on the role of biobanking in Covid-19 pandemic.

中文翻译：

---

生物库在COVID-19大流行中的关键作用

正确收集传染性生物样品对于更好地了解疾病的发病机理和健康至关重要。这些珍贵的样品存储在生物库中。COVID-19是一种由最近发现的新型冠状病毒SARS-COV-2引起的传染病。尽管各种机构开发疫苗的努力已显示出一些积极成果，但目前尚无针对这种病毒的特定药物。对发病机理的了解有限，是制定干预措施的关键缺口。获得COVID-19生物样品进行研究可以提供对该疾病的更多见解。印度医学研究理事会（ICMR）将国家肝病生物库（NLDB）指定为收集和存储COVID-19生物样品以进行研究的专用设施之一。收集样本 处理，并以适当的安全性存储在NLDB中。在此小型审查中，我们尝试全面介绍生物银行在Covid-19大流行中的作用。